Bayesian models prioritize compounds for Schistosoma mansoni assays
Eight stage/time-specific Bayesian classifiers trained on historical phenotypic measurements guided prospective selection of predicted active and inactive commercial compounds. In-vitro assays reported 48% and 34% hit fractions for somules and adults, followed by triage of five compounds. The selected-set fractions are not unbiased head-to-head screening rates; no animal cure, clinical mechanism, safety or efficacy is established.
Technology: Bayesian classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports prospective somule/adult screens and prioritized compounds after triage.
- Still unknown: Compound-specific prior evidence and complete supplementary access remain open; no clinical inference.
- AI role: Stage/time-specific Bayesian models guided selection of assay compounds, with human curation and triage.
Evidence sources: https://doi.org/10.1021/acsinfecdis.0c00754
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: PMC-indexed primary text; PubMed primary metadata. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.